company background image
NOX logo

Noxopharm ASX:NOX Stock Report

Last Price

AU$0.067

Market Cap

AU$19.6m

7D

-9.5%

1Y

-36.2%

Updated

28 Mar, 2024

Data

Company Financials

NOX Stock Overview

Noxopharm Limited, a biotech company, discovers and develops treatments for cancer and inflammation, and mRNA vaccines in Australia.

NOX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Noxopharm Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Noxopharm
Historical stock prices
Current Share PriceAU$0.067
52 Week HighAU$0.17
52 Week LowAU$0.033
Beta0.71
1 Month Change11.67%
3 Month Change-5.63%
1 Year Change-36.19%
3 Year Change-89.37%
5 Year Change-82.60%
Change since IPO-63.78%

Recent News & Updates

Recent updates

Is Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?

Jan 04
Is Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?

We're Keeping An Eye On Noxopharm's (ASX:NOX) Cash Burn Rate

Jul 22
We're Keeping An Eye On Noxopharm's (ASX:NOX) Cash Burn Rate

Is Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?

Feb 27
Is Noxopharm (ASX:NOX) In A Good Position To Deliver On Growth Plans?

We Think Noxopharm (ASX:NOX) Can Easily Afford To Drive Business Growth

Nov 10
We Think Noxopharm (ASX:NOX) Can Easily Afford To Drive Business Growth

Is Noxopharm (ASX:NOX) Using Debt Sensibly?

Jun 04
Is Noxopharm (ASX:NOX) Using Debt Sensibly?

Noxopharm (ASX:NOX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Feb 17
Noxopharm (ASX:NOX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

These 4 Measures Indicate That Noxopharm (ASX:NOX) Is Using Debt Extensively

Sep 04
These 4 Measures Indicate That Noxopharm (ASX:NOX) Is Using Debt Extensively

Shareholder Returns

NOXAU BiotechsAU Market
7D-9.5%2.7%1.5%
1Y-36.2%1.4%11.6%

Return vs Industry: NOX underperformed the Australian Biotechs industry which returned 1.4% over the past year.

Return vs Market: NOX underperformed the Australian Market which returned 11.6% over the past year.

Price Volatility

Is NOX's price volatile compared to industry and market?
NOX volatility
NOX Average Weekly Movement18.7%
Biotechs Industry Average Movement11.5%
Market Average Movement8.7%
10% most volatile stocks in AU Market17.1%
10% least volatile stocks in AU Market3.2%

Stable Share Price: NOX's share price has been volatile over the past 3 months.

Volatility Over Time: NOX's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
2015n/aGisela Mautnerhttps://www.noxopharm.com

Noxopharm Limited, a biotech company, discovers and develops treatments for cancer and inflammation, and mRNA vaccines in Australia. It primarily develops Veyonda, a formulation of idronoxil for the treatment of solid tumors. The company also develops LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; and IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types.

Noxopharm Limited Fundamentals Summary

How do Noxopharm's earnings and revenue compare to its market cap?
NOX fundamental statistics
Market capAU$19.58m
Earnings (TTM)-AU$12.13m
Revenue (TTM)AU$3.88m

5.1x

P/S Ratio

-1.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NOX income statement (TTM)
RevenueAU$3.88m
Cost of RevenueAU$6.30m
Gross Profit-AU$2.43m
Other ExpensesAU$9.70m
Earnings-AU$12.13m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.041
Gross Margin-62.60%
Net Profit Margin-312.86%
Debt/Equity Ratio0%

How did NOX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.